10x Genomics, Inc. (NASDAQ:TXG) Shares Purchased by VitalStone Financial LLC

VitalStone Financial LLC lifted its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 59,900.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,600 shares of the company’s stock after purchasing an additional 3,594 shares during the quarter. VitalStone Financial LLC’s holdings in 10x Genomics were worth $201,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC raised its stake in 10x Genomics by 56.4% in the 3rd quarter. FMR LLC now owns 12,666,998 shares of the company’s stock worth $522,514,000 after acquiring an additional 4,565,400 shares during the last quarter. ARK Investment Management LLC raised its stake in 10x Genomics by 35.0% in the 4th quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company’s stock worth $226,150,000 after acquiring an additional 1,047,827 shares during the last quarter. SVB Wealth LLC raised its stake in 10x Genomics by 92.1% in the 4th quarter. SVB Wealth LLC now owns 1,446,552 shares of the company’s stock worth $80,949,000 after acquiring an additional 693,422 shares during the last quarter. Norges Bank purchased a new position in 10x Genomics in the 4th quarter worth $36,262,000. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in 10x Genomics by 32.9% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,283,530 shares of the company’s stock worth $127,786,000 after acquiring an additional 565,059 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Stifel Nicolaus reduced their price objective on 10x Genomics from $63.00 to $53.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. TD Cowen lowered 10x Genomics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $57.00 to $32.00 in a research note on Wednesday, May 1st. Jefferies Financial Group assumed coverage on 10x Genomics in a research note on Monday, June 3rd. They set a “hold” rating and a $24.00 price objective for the company. Canaccord Genuity Group reduced their price objective on 10x Genomics from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 29th. Finally, The Goldman Sachs Group reduced their price objective on 10x Genomics from $30.00 to $26.00 and set a “sell” rating for the company in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, 10x Genomics presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.62.

10x Genomics Stock Performance

Shares of 10x Genomics stock opened at $22.18 on Tuesday. The stock’s 50 day simple moving average is $27.49 and its 200-day simple moving average is $39.40. 10x Genomics, Inc. has a 1-year low of $21.14 and a 1-year high of $63.57.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). 10x Genomics had a negative return on equity of 30.85% and a negative net margin of 42.20%. The firm had revenue of $141.01 million for the quarter, compared to analysts’ expectations of $142.24 million. During the same period in the prior year, the firm posted ($0.44) earnings per share. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. On average, equities analysts expect that 10x Genomics, Inc. will post -1.55 EPS for the current year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Justin J. Mcanear sold 2,936 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $71,344.80. Following the sale, the chief financial officer now owns 146,203 shares of the company’s stock, valued at $3,552,732.90. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Benjamin J. Hindson sold 4,087 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $99,314.10. Following the sale, the insider now owns 350,055 shares of the company’s stock, valued at $8,506,336.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Justin J. Mcanear sold 2,936 shares of the stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total value of $71,344.80. Following the completion of the transaction, the chief financial officer now directly owns 146,203 shares in the company, valued at approximately $3,552,732.90. The disclosure for this sale can be found here. Insiders have sold a total of 11,900 shares of company stock valued at $289,170 over the last quarter. 10.03% of the stock is owned by company insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.